医学
免疫疗法
食管鳞状细胞癌
放化疗
T细胞
癌症研究
免疫系统
新辅助治疗
Cd4 t细胞
细胞
食管
基底细胞
完全响应
肿瘤科
癌
化疗
放射治疗
免疫学
T细胞受体
抗体
内科学
肿瘤微环境
细胞毒性T细胞
抗原
PD-L1
作者
Xin-Yun Song,Zhichao Liu,Hui-Hui Hu,Yue Li,Lin Lin,Yang Yang,Hong-Xuan Li,Wen Feng,Qin Zhang,Xu-Wei Cai,Jun Liu,Wen Yu,Zhi-Gang Li,Xiaolong Fu
标识
DOI:10.1016/j.xcrm.2026.103162
摘要
The optimal integration of immunotherapy with chemoradiotherapy (CRT) in neoadjuvant treatment of esophageal squamous cell carcinoma (ESCC) remains unclear. We integrate paired pre- and post-treatment single-cell RNA sequencing and TCR sequencing data from patients receiving neoadjuvant immunochemotherapy (NICT), chemoradiotherapy (NCRT), or immuno-chemoradiotherapy (NICRT) to investigate how these regimens shape intratumoral CD8 + T cell responses. Favorable responses to NICT are associated with maintenance of pre-existing CXCL13 + PD-1 + CD8 + T cells and post-treatment enrichment of a progenitor-like CD8Tex_CXCR4 subset. In contrast, CRT responders show reduced CXCL13 + CD8 + T cells and enrichment of clonally expanded, cytotoxic PD-1 - CD8Teff_NIBAN1 cells. These divergent programs are validated in public datasets and independent prospective cohorts. In murine models, radiotherapy limits PD-1 + T cell expansion, whereas induction anti-PD-1 treatment followed by radiotherapy improves tumor control. Together, these findings reveal distinct CD8 + T cell programs associated with response to different neoadjuvant modalities and provide a cellular rationale for optimizing immunotherapy-radiotherapy sequencing.
科研通智能强力驱动
Strongly Powered by AbleSci AI